MISO-FEM TABLETS

Indications

• Gastric ulcer
• Duodenal ulcer
• NSAID-induced peptic ulcer
• Termination of pregnancy following mifepristone
• Management of miscarriage

Dosage

Children: Oral preparations are not licensed for use in children under 3 years. For children aged 1–5 months, the dose is 1 mg/kg 3 times a day. For children aged 6 months to 2 years

Adults: For gastric and duodenal ulcers, the typical adult dose is 150 mg orally twice daily. For termination of pregnancy following mifepristone, the recommended dose is 400 micrograms orally.

Mechanism of action

Misoprostol stimulates prostaglandin E1 receptors on parietal cells in the stomach to reduce gastric acid secretion. It increases mucus and bicarbonate secretion, thickening the mucosal bilayer, and promotes the generation of new cells. In the uterus, Misoprostol binds to smooth muscle cells to enhance the strength and frequency of contractions, while also degrading collagen and reducing cervical tone.

Pharmacodynamics

Misoprostol acts as a prostaglandin E1 analog which is effective in reducing the risk of NSAID-induced gastric ulcers and is utilized in obstetric applications such as miscarriage management and abortion. Its onset of action varies by route: oral (8 minutes), sublingual (11 minutes), vaginal (20 minutes), and rectal (100 minutes), with durations of action ranging from approximately 2 to 4 hours.

Pharmacokinetics

Misoprostol is rapidly absorbed after oral administration, with bioavailability affected by food. It undergoes extensive first-pass metabolism, leading to a half-life of about 20-40 minutes. The drug is metabolized in the liver and its metabolites are eliminated primarily through the urine. The pharmacokinetic profile varies with administration route and formulation.

Contra-indications

• Hypersensitivity to misoprostol or any of its components
• Pregnancy (for certain indications such as termination)
• History of uterine rupture
• Severe cardiovascular disease
• Conditions where hypotension might precipitate severe complications

Adverse effects

• Diarrhea
• Abdominal pain
• Nausea
• Vomiting
• Headache
• Dizziness
• Uterine rupture (rare)
• Chills
• Fever
• Hot flushes
• Hypotension
• Malaise
• Toxic shock syndrome (rare)

Interactions

• Oxytocin (unknown additive effect)
• NSAIDs may have diminished efficacy when misoprostol is used concurrently

Precautions

• Monitor for coagulopathy during treatment
• Use with caution in patients with a history of inflammatory bowel disease
• Caution in patients with cardiovascular disease
• Patients should be informed about potential for diarrhea and other gastrointestinal side effects

Pregnancy

Not recommended during pregnancy except for specific medical indications such as termination of pregnancy following mifepristone, as it may induce contractions and lead to miscarriage.

Breast-feeding

Misoprostol is excreted in breast milk; caution is advised when administered to nursing mothers.

Storage

Store below 25°C. Protect from light and moisture.

Formulations

• Tablets: 200 micrograms, 400 micrograms
• Pessaries: 100 micrograms
• Oral solution

Indications

• Oral medications for improved solubility
• Topical applications for enhanced delivery of active ingredients
• Parenteral formulations for intravenous administration
• Vaccines delivered as emulsions for enhanced immune response

Dosage

Children: Refer to specific product information for dosage guidelines, as this varies by formulation and intended use.

Adults: Refer to specific product information for dosage guidelines, as this varies by formulation and intended use.

Mechanism of action

The mechanism of action of a dispersion often involves the physical distribution of active pharmaceutical ingredients in a medium, which can lead to increased surface area and improved interaction with biological membranes. For example, in emulsions, the dispersion of oil in water can enhance the absorption of lipid-soluble drugs.

Pharmacodynamics

Pharmacodynamics of dispersions relates to how the dispersed formulation affects the body. The presence of surfactants or emulsifying agents can modify drug release rates, enhance absorption, and improve therapeutic effects. The effectiveness of a dispersion is influenced by particle size, viscosity, and the nature of the dispersing medium.

Pharmacokinetics

The pharmacokinetics of dispersions depend on the formulation type and the route of administration. Key factors include the rate of dispersion breakdown, absorption through biological membranes, distribution within the body, metabolism, and excretion of the active ingredients. Dispersions can alter the onset of action and duration of effect based on their formulation characteristics.

Pregnancy

Consult with a healthcare provider before use. Safety in pregnancy is not established for all formulations.

Breast-feeding

Consult with a healthcare provider before use. Safety during breastfeeding may vary depending on the formulation.

Storage

Store in a cool, dry place away from direct sunlight. Follow specific storage instructions provided by the manufacturer.

Indications

• Dry eye syndrome
• Ocular lubrication
• Topical drug delivery
• Thickening agent in pharmaceutical formulations
• Emulsifying agent

Dosage

Children: Refer to specific product guidelines for dosing, as HPMC is used in various formulations and concentrations.

Adults: Refer to specific product guidelines for dosing, as HPMC is used in various formulations and concentrations.

Mechanism of action

HPMC works by forming a gel-like structure when hydrated, which can retain moisture and provide lubrication. In ocular formulations, it increases the viscosity of the solution, prolonging the contact time with the eye surface, thereby enhancing the therapeutic effect. It also acts as a stabilizer in emulsions and suspensions, preventing the separation of ingredients.

Pharmacodynamics

The pharmacodynamic properties of HPMC are primarily associated with its ability to modify viscosity and create a protective barrier when applied topically. In ophthalmic formulations, it helps to maintain tear film stability and reduces evaporation, which is beneficial in treating dry eye conditions. Additionally, it facilitates the sustained release of active pharmaceutical ingredients from formulations.

Pharmacokinetics

HPMC is not significantly absorbed systemically when applied topically or used in ocular formulations. Its metabolism involves hydrolysis and microbial degradation in the gastrointestinal tract when ingested. The elimination of HPMC from the body is primarily via feces, as it is not actively absorbed into the bloodstream.

Pregnancy

HPMC (Hydroxypropyl Methylcellulose) is generally considered safe for use during pregnancy, but it is always best to consult a healthcare provider.

Breast-feeding

HPMC is unlikely to be harmful during breastfeeding, but nursing mothers should consult a healthcare provider before use.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Eye drops
• Ophthalmic gel
• Oral capsules
• Oral tablets
• Topical preparations

Mechanism of action

Misoprostol is a synthetic prostaglandin E1 analog that stimulates prostaglandin E1 receptors on parietal cells in the stomach to reduce gastric acid secretion. Mucus and bicarbonate secretion are also increased along with thickening of the mucosal bilayer so the mucosa can generate new cells. Misoprostol binds to smooth muscle cells in the uterine lining to increase the strength and frequency of contractions as well as degrade collagen and reduce cervical tone. Misoprostol enhances natural gastromucosal defense mechanisms and healing in acid-related disorders, probably by increasing production of gastric mucus and mucosal secretion of bicarbonate. Misoprostol inhibits basal and nocturnal gastric acid secretion by direct action on the parietal cells; also inhibits gastric acid secretion stimulated by food, histamine, and pentagastrin. It decreases pepsin secretion under basal, but not histamine stimulation. Misoprostol has no significant effect on fasting or postprandial gastrin or intrinsic factor output.

Pharmacodynamics

Misoprostol is a prostaglandin E1 analog used to reduce the risk of NSAID induced gastric ulcers by reducing secretion of gastric acid from parietal cells. Misoprostol is also used to manage miscarriages and used alone or in combination with mifepristone for first trimester abortions. An oral dose of misoprostol has an 8 minute onset of action and a duration of action of approximately 2 hours, a sublingual dose has an 11 minute onset of action and a duration of action of approximately 3 hours, a vaginal dose has a 20 minute onset of action and a duration of action of approximately 4 hours, and a rectal dose has a 100 minute onset of action and a duration of action of approximately 4 hours.